|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Deerfield leads the funding in creation of Akari Therapeutics Plc which is created through the Celsus Therapeutics Plc acquisition of Volution Immuno Pharmaceuticals.
Shares of Celsus Therapeutics (CLTX) plunged more to a 52-week low in morning trading Tuesday after the biotech company announced the results of its dermatitis treatment in a mid-stage trial.
MRX-6 Cream Did Not Demonstrate Separation From Vehicle in Primary Endpoint of Percent Improvement in the Investigator's Global Assessment
Topline Data From Double-Blind Portion of Trial Expected by End of February, 2015
Phase II Dose Ranging Clinical Trial in Atopic Dermatitis Expected to Begin in First Quarter of 2015
Results Expected in Fourth Quarter of 2014